Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In childhood leukemia study, aggressive chemotherapy cuts deaths by 37%

02.10.2003


More than a third of children who die from a particularly deadly form of leukemia would be saved if doctors used three existing drugs more aggressively – administering them at much higher doses and over a longer period of time. That is one of several important conclusions drawn from a long-term study, published in the October issue of the Journal of Clinical Oncology, that tested a high-dose drug regimen in 125 young leukemia patients and tracked their outcomes for an average of nine years.



The study, conducted by researchers at nine universities and research hospitals, was led by Barbara L. Asselin, M.D., associate professor of Pediatrics and Oncology at the James P. Wilmot Cancer Center at the University of Rochester. It focused on children with T-cell acute lymphoblastic leukemia, or T-ALL, which accounts for 15 percent of all childhood leukemia cases and is fatal in nearly four in 10 children. While dozens of drugs are routinely used to treat children with the disease, the study sheds new light on the fundamental questions about their use: Which combination of those drugs is most effective? And, what are the highest doses that can be given without subjecting children to additional risks – such as kidney damage and neurological problems – that might be caused by the powerful drugs themselves?

To find out, the researchers drew on earlier studies that had pointed to the effectiveness of three cancer-killing drugs – methotrexate, asparaginase, and doxorubicin. The researchers devised an experimental regimen in which all three would be administered at whopping doses – up to five times higher than usual – and for durations of several months instead of weeks. Between 1981 and 2000, 125 children with T-ALL received the experimental treatment. Afterward, each patient’s progress was followed by the researchers for an average of nine years. More than 25 percent of the patients were followed into their 20s, and some into their early 30s. The researchers were interested not only in whether the children survived the cancer, but also whether the high-dose chemotherapy produced any debilitating long-term effects.


Of the 125 children studied, 93 of them were cured, yielding a survival rate of 75 percent compared to survival rates of between 60 and 65 percent for treatment regimens that used much lower drug doses. Years after treatment, despite the more aggressive chemotherapy, the patients did not experience medical problems beyond those reported in those who had received lower doses of the drugs, with one exception. Patients who had received higher doses of doxorubicin experienced slightly higher rates of cardiomyopathy, a weakening of the heart muscle that can usually be controlled with medication.

"This study tells us, without question, that we should be using these drugs much more aggressively," said Asselin. "Giving these drugs at much higher dosages dramatically improves a child’s chances for survival, and does not pose a significantly greater risk for long-term negative effects. The evidence is so compelling that we are recommending that this new approach become the standard treatment for all children diagnosed with this form of leukemia."

In addition to high-dose chemotherapy, children in the study received low-dose radiation therapy to the brain, where cancerous cells are most likely to survive chemotherapy and cause a relapse of leukemia in the future. Asselin and her colleagues credit the combination of chemotherapy and radiation with preventing relapse among the majority of children in the study, thereby minimizing the greatest threat to their long-term survival. Equally important, the use of low-dose radiation to the brain did not result in a decline in cognitive abilities that had been reported in earlier studies in which children had received higher does of radiation.

"Our goal in this study, and in our careers as researchers, is to find the right balance of treatment for these children," said Asselin. "We want to deliver treatment that is powerful enough to kill their cancer, yet not so toxic that the treatment itself robs them of a normal life afterward. We want them to be healthy – to grow up to play and have fun and do well in school and have a normal quality of life."

The study was funded by the National Institutes of Health and conducted by the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Co-authors of the paper were John M. Goldberg, Lewis B. Silverman, Donna E. Levy, Virginia Kimball Dalton, Richard D. Gelber, Leslie Lehmann, Harvey J. Cohen, and Stephen E. Sallan.

Chris DiFrancesco | EurekAlert!
Further information:
http://www.urmc.rochester.edu/

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>